| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9959834 | Journal of the American College of Cardiology | 2005 | 5 Pages |
Abstract
Many patients treated with spironolactone for CHF do not receive needed follow-up of potassium or creatinine concentrations, although hyperkalemia and renal dysfunction are common. Elevated baseline creatinine predicts patients at high risk. Physician education of the risks of spironolactone and the need for follow-up is essential.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Keyur B. MD, Krishnamurti BS, Robert MD, Stephen S. (FACC),